Guillermo Garcia-Manero - Profile and Journalist Details

Beats

Content

Total articles 136

• Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia - Bone Marrow Transplantation

  By Jayastu Senapati, Guillermo Garcia-Manero, Courtney DiNardo, Gautam Borthakur, Tapan M Kadia, Elias Jabbour, Nicholas Short, Hussein Abbas, Naveen Pemmaraju, Uday Popat, Sanam Loghavi, Guilin Tang, Farhad Ravandi, Hagop Kantarjian| Nature Verified Despite the improvement in overall outcomes of patients with acute myeloid leukemia (AML), some high-risk disease subsets continue to fare dismally. AML with TP53 aberrations (mutations, deletions) is one such subset of high-risk AML with a median survival of about 6–9 months [1,2,3]

  By Jayastu Senapati, Guillermo Garcia-Manero, Courtney DiNardo, Gautam Borthakur, Tapan M Kadia, Elias Jabbour, Nicholas Short, Hussein Abbas, Naveen Pemmaraju, Uday Popat, Sanam Loghavi, Guilin Tang, Farhad Ravandi, Hagop Kantarjian · Nature

  Apr. 10, 2025

• VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial | Blood Cancer Journal

  By Mahesh Swaminathan, Courtney DiNardo, Naveen Pemmaraju, Guillermo Garcia-Manero, Ghayas C. Issa, Gautam Borthakur, Farhad Ravandi, Guillermo Montalban-Bravo, Tapan M Kadia, Yesid Reyes Alvarado, Elias Jabbour, Nicholas Short, William Wierda, Steven Kornblau, Hagop Kantarjian| Nature Verified To the Editor:The advent of VEN (VEN) has changed the treatment paradigm of acute myeloid leukemia (AML). Currently, venetoclax (VEN), in combination with a hypomethylating agent (HMA), is approved for the treatment of adult patients with AML unsuitable for intensive chemotherapy or frontline treatment of patients ≥75 years [1]

  By Mahesh Swaminathan, Courtney DiNardo, Naveen Pemmaraju, Guillermo Garcia-Manero, Ghayas C. Issa, Gautam Borthakur, Farhad Ravandi, Guillermo Montalban-Bravo, Tapan M Kadia, Yesid Reyes Alvarado, Elias Jabbour, Nicholas Short, William Wierda, Steven Kornblau, Hagop Kantarjian · Nature

  Apr. 01, 2025

As seen in

Company Info

Blood Cancer Journal